Protagonist Therapeutics (PTGX) Current Assets (2015 - 2026)

Protagonist Therapeutics has disclosed Current Assets across 12 years of filings, most recently posting $613.5 million for Q1 2026.

• Current Assets for Q1 2026 came in at $613.5 million, up 1.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $613.5 million (up 1.25% YoY), and the FY2025 annual result was $577.6 million, down 2.38% from the prior year.
• Current Assets came in at $613.5 million for Q1 2026 at Protagonist Therapeutics, up from $577.6 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $627.6 million in Q1 2024 to a low of $235.7 million in Q1 2023.
• The 5-year median for Current Assets is $476.8 million (2024), against an average of $450.1 million.
• Across the five-year window, Current Assets tumbled 30.97% in 2023 and soared 166.21% in 2024, its largest moves.
• Protagonist Therapeutics' Current Assets stood at $243.1 million in 2022, then surged by 46.28% to $355.6 million in 2023, then soared by 66.39% to $591.6 million in 2024, then slipped by 2.38% to $577.6 million in 2025, then climbed by 6.21% to $613.5 million in 2026.
• The last three Current Assets figures came in at $613.5 million (Q1 2026), $577.6 million (Q4 2025), and $586.4 million (Q3 2025), per Business Quant data.